494 reports of this reaction
2.1% of all BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE reports
#13 most reported adverse reaction
DRUG DOSE OMISSION BY DEVICE is the #13 most commonly reported adverse reaction for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, manufactured by AstraZeneca Pharmaceuticals LP. There are 494 FDA adverse event reports linking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE to DRUG DOSE OMISSION BY DEVICE. This represents approximately 2.1% of all 23,211 adverse event reports for this drug.
Patients taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE who experience drug dose omission by device should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION BY DEVICE is a less commonly reported adverse event for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, but still significant enough to appear in the safety profile.
In addition to drug dose omission by device, the following adverse reactions have been reported for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE:
The following drugs have also been linked to drug dose omission by device in FDA adverse event reports:
DRUG DOSE OMISSION BY DEVICE has been reported as an adverse event in 494 FDA reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION BY DEVICE accounts for approximately 2.1% of all adverse event reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, making it a notable side effect.
If you experience drug dose omission by device while taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.